Aquestive Therapeutics To Present Data From Pharmacokinetic And Pharmacodynamic Studies For Anaphylm At American College Of Allergy Asthma And Immunology Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Aquestive Therapeutics, Inc. (NASDAQ:AQST) will present two posters at the American College of Allergy Asthma and Immunology (ACAAI) annual meeting, showcasing positive data from pharmacokinetic and pharmacodynamic studies of Anaphylm™ (epinephrine) Sublingual Film. The company's CEO, Dan Barber, expressed excitement about the results and the potential of Anaphylm for the treatment of acute allergic reactions, pending FDA approval.
November 10, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aquestive Therapeutics will present positive data from studies of Anaphylm at the ACAAI annual meeting. The results could potentially lead to FDA approval and a significant advancement in the treatment of acute allergic reactions.
The positive data from the studies of Anaphylm, if leading to FDA approval, could significantly boost Aquestive Therapeutics' market position and stock value. The news is highly relevant as it directly pertains to one of the company's key products.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100